Live Breaking News & Updates on Jean Pierre Sommadossi

Stay updated with breaking news from Jean pierre sommadossi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A. ....

United States , Jean Pierre Sommadossi , Jonae Barnes , Qi Huang , Alina Jucov , Atea Pharmaceuticals Inc , Globenewswire Inc , Corporate Communications , Atea Pharmaceuticals , European Association For The Study , While The Company , Include New Antiviral Efficacy Results , Lead In Cohort , Ongoing Phase , Also Highlight , High Prevalence , Resistance Associated Substitutions , Chief Executive Officer , European Time , Lead In Cohort Results From , Week Combination Regimen , Chronic Hepatitisc Virus , Favorable Antiviral Profile , High Resistance , Low Risk , Drug Interactions ,

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-In-Class Combination Profile Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis...

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also H ....

United States , Alina Jucov , Qi Huang , Jonae Barnes , Jean Pierre Sommadossi , Corporate Communications , While The Company , Atea Pharmaceuticals , Atea Pharmaceuticals Inc , Founder Of Atea Pharmaceuticals We , Include New Antiviral Efficacy Results , Lead In Cohort , Ongoing Phase , Also Highlight , High Prevalence , Resistance Associated Substitutions , European Association , Chief Executive Officer , European Time , Lead In Cohort Results From , Week Combination Regimen , Chronic Hepatitisc Virus , Favorable Antiviral Profile , High Resistance , Low Risk , Drug Interactions ,

Atea Pharmaceuticals Reports First Quarter 2024 Financial Results And Provides Business Update

Atea Pharmaceuticals Reports First Quarter 2024 Financial Results And Provides Business Update
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United States , Jean Pierre Sommadossi , European Society Of Clinical Microbiology Infectious Diseases , Atea Pharmaceuticals Inc , Development Expenses , Program For Second Generation Protease Inhibitors , Drug Administration , Atea Or Company , Full Enrollment Achieved , Global Phase , Results Expected , Report Complete , Presentations Showcasing Preclinical , New Phase , European Association , Chief Executive Officer , High Risk Outpatients , Fast Track , Second Generation Protease Inhibitors , Bemnifosbuvir Data Presented , European Society , Clinical Microbiology , Infectious Diseases , Cash Equivalents , Marketable Securities , Administrative Expenses ,

Marquette Asset Management LLC Buys 22,301 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Marquette Asset Management LLC raised its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) by 89.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,166 shares of the company’s stock after purchasing an additional 22,301 shares during the period. Marquette […] ....

Dwayne Foster , Jean Pierre Sommadossi , Atea Pharmaceuticals Inc , Securities Exchange Commission , Atea Pharmaceuticals , Acuitas Investments , China Universal Asset Management Co , Sg Americas Securities , News Ratings For Atea Pharmaceuticals Daily , Marquette Asset Management , Capital Management , Quarter For Atea Pharmaceuticals , Atea Pharmaceuticals Trading , Free Report , Asset Management , Universal Asset Management , Gladius Capital Management , Get Free Report , Pierre Sommadossi , Exchange Commission , Visit Holdingschannel , Atea Pharmaceuticals Daily , Nasdaq Avir , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript February 28, 2024 Atea Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Fourth Quarter 2023 Financial Results and Business Update […] ....

Jean Pierre Sommadossi , John Vavricka , Janet Hammond , Andrea Corcoran , World Health Organization , World Health , Fast Track , Pierre Sommadossi , Highest Tax ,